Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 4/20 | 0.50 |
| ▸ | CREBBP | Q92793 | 4/20 | 0.50 |
| ▸ | EP300 | Q09472 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 5/20 | 0.42 |
| ▸ | NPC1 | O15118 | 4/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | CASP7 | P55210 | 1/20 | 0.35 |
| ▸ | GFER | P55789 | 1/20 | 0.35 |
| ▸ | NISCH | Q9Y2I1 | 2/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15508279 | 1.00 | BRD4 (0.50) | BRD4CREBBPEP300RAB9ANPC1 | |
| SCHEMBL19225173 | 1.00 | BRD4 (0.50) | BRD4CREBBPEP300RAB9ANPC1 | |
| SCHEMBL30570961 | 1.00 | BRD4 (0.50) | BRD4CREBBPEP300RAB9ANPC1 | |
| SCHEMBL29898376 | 1.00 | BRD4 (0.50) | BRD4CREBBPEP300RAB9ANPC1 | |
| SCHEMBL28519858 | 0.79 | BRD4 (0.37) | BRD4CREBBPEP300RAB9ANPC1 | |
| SCHEMBL29988014 | 0.79 | BRD4 (0.37) | BRD4CREBBPEP300RAB9ANPC1 | |
| SCHEMBL4911575 | 0.78 | BRD4 (0.47) | BRD4CREBBPEP300RAB9ANPC1 | |
| SCHEMBL4910769 | 0.78 | BRD4 (0.47) | BRD4CREBBPEP300RAB9ANPC1 | |
| SCHEMBL4906005 | 0.78 | BRD4 (0.47) | BRD4CREBBPEP300RAB9ANPC1 | |
| SCHEMBL30124448 | 0.78 | SMN1; SMN2 (0.48) | BRD4CREBBPEP300RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117143018-A | Synthesis method of rare earth catalytic nitrogen-containing heterocyclic compound | 温州大学新材料与产业技术研究院 | 2023-12-01 | — | — | CN | disclosed |
| CN-112266364-B | Preparation method of tetrahydroquinoxaline compound | 云南民族大学 | 2023-11-17 | — | — | CN | disclosed |
| CN-116751170-A | Method for directly preparing semi-hydrogenated nitrogen-containing aromatic heterocyclic compound from sugar | 浙江大学 | 2023-09-15 | — | — | CN | disclosed |
| CN-114957138-A | Quinoxaline asymmetric hydrogenation method | 哈尔滨工业大学（深圳） | 2022-08-30 | — | — | CN | disclosed |
| CN-109053567-B | Method for reducing nitrogen-containing heterocyclic compound by hydrogen transfer | 西南石油大学 | 2021-09-21 | — | — | CN | disclosed |
| US-11084831-B1 | Benzopiperazine compositions as BET bromodomain inhibitors | FORMA THERAPEUTICS, INC. (US) | 2021-08-10 | — | — | US | disclosed |
| CN-112266364-A | Preparation method of tetrahydroquinoxaline compound | 云南民族大学 | 2021-01-26 | — | — | CN | disclosed |
| CN-110483420-B | Preparation method of tetrahydroquinoxaline compound | 云南民族大学 | 2021-01-15 | — | — | CN | disclosed |
| US-10822364-B2 | Compositions and methods comprising conductive metal organic frameworks and uses thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2020-11-03 | — | — | US | disclosed |
| US-10703764-B2 | Benzopiperazine compositions as BET bromodomain inhibitors | FORMA THERAPEUTICS, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| EP-2609103-B1 | RUTHENIUM-DIAMINE COMPLEXES AND METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUNDS | TAKASAGO PERFUMERY CO LTD (JP) | 2015-08-19 | — | — | EP | disclosed |
| US-20150210657-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE AMINE | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2015-07-30 | — | — | US | disclosed |
| WO-2015074081-A1 | BENZOPIPERAZINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | BAIR KENNETH W (US) | 2015-05-21 | — | — | WO | disclosed |
| US-20150094468-A1 | NOVEL DIAMINE COMPOUND AND METAL COMPLEXES, AND METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUNDS | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2015-04-02 | — | — | US | disclosed |
| EP-2609103-A1 | RUTHENIUM-DIAMINE COMPLEXES AND METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUNDS | Takasago International Corporation (JP) | 2013-07-03 | — | — | EP | disclosed |
| US-20130158276-A1 | RUTHENIUM-DIAMINE COMPLEXES AND METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUNDS | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2013-06-20 | — | — | US | disclosed |
| US-20130158276-A1 | RUTHENIUM-DIAMINE COMPLEXES AND METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUNDS | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2013-06-20 | — | — | US | disclosed |
| WO-2013026874-A1 | CDK9 INHIBITORS IN THE TREATMENT OF MIDLINE CARCINOMA | LEAD DISCOVERY CENTER GMBH (DE) | 2013-02-28 | — | — | WO | disclosed |
| WO-2013026890-A1 | SUSCEPTIBILITY TO SELECTIVE CDK9 INHIBITORS | LEAD DISCOVERY CENTER GMBH (DE) | 2013-02-28 | — | — | WO | disclosed |
| WO-2012026201-A1 | RUTHENIUM-DIAMINE COMPLEXES AND METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUNDS | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2012-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158276-A1 | RUTHENIUM-DIAMINE COMPLEXES AND METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUNDS | ADH1A, ADH1C, ADH5 | BRD4 2337/4885CREBBP 3236/4885EP300 1087/4885 |
| US-10703764-B2 | Benzopiperazine compositions as BET bromodomain inhibitors | BRD4, BRPF3, BRD7 | BRD4 1/4885CREBBP 28/4885EP300 15/4885 |
| US-10822364-B2 | Compositions and methods comprising conductive metal organic frameworks and uses thereof | ILK, AOC1, OCIAD2 | BRD4 2101/4885CREBBP 4218/4885EP300 1762/4885 |
| US-11084831-B1 | Benzopiperazine compositions as BET bromodomain inhibitors | BRD4, BRPF3, BRD7 | BRD4 1/4885CREBBP 28/4885EP300 15/4885 |
| US-20150210657-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE AMINE | HRH3, HRH1, ATIC | BRD4 3939/4885CREBBP 4212/4885EP300 2178/4885 |
| US-20150094468-A1 | NOVEL DIAMINE COMPOUND AND METAL COMPLEXES, AND METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUNDS | AOC1, SAT1, ODC1 | BRD4 1346/4885CREBBP 3125/4885EP300 1428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.